108 related articles for article (PubMed ID: 9032539)
1. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma.
Shiina H; Igawa M; Urakami S; Shirakawa H; Ishibe T; Kawanishi M
Eur Urol; 1997; 31(1):73-80. PubMed ID: 9032539
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Nagami H; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T; Kawanishi M
Cancer; 1996 Oct; 78(8):1762-74. PubMed ID: 8859190
[TBL] [Abstract][Full Text] [Related]
3. Relationship of genetic instability with immunoreactivities for p53 protein and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Yagi H; Urakami S; Shirakawa H; Ishibe T
Eur Urol; 1996; 30(1):80-8. PubMed ID: 8854073
[TBL] [Abstract][Full Text] [Related]
4. Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma.
Sejima T; Miyagawa I
Eur Urol; 1999; 35(3):242-8. PubMed ID: 10072628
[TBL] [Abstract][Full Text] [Related]
5. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma.
Gelb AB; Sudilovsky D; Wu CD; Weiss LM; Medeiros LJ
Cancer; 1997 Nov; 80(9):1768-75. PubMed ID: 9351546
[TBL] [Abstract][Full Text] [Related]
6. Biologic behavior of and p53 overexpression in multifocal renal cell carcinoma of clear cell type: an immunohistochemical study correlating grading, staging, and proliferation markers.
Haitel A; Wiener HG; Blaschitz U; Marberger M; Susani M
Cancer; 1999 Apr; 85(7):1593-8. PubMed ID: 10193951
[TBL] [Abstract][Full Text] [Related]
7. P53 mutations and other prognostic factors of renal cell carcinoma.
Girgin C; Tarhan H; Hekimgil M; Sezer A; Gürel G
Urol Int; 2001; 66(2):78-83. PubMed ID: 11223748
[TBL] [Abstract][Full Text] [Related]
8. Incidence of apoptosis, cell proliferation and P53 expression in renal cell carcinomas.
Tannapfel A; Hahn HA; Katalinic A; Fietkau RJ; Kühn R; Wittekind CW
Anticancer Res; 1997; 17(2A):1155-62. PubMed ID: 9137464
[TBL] [Abstract][Full Text] [Related]
9. DNA cytophotometry in renal cell carcinoma: a significant prognostic factor?
Feil G; Mittermüller B; Bichler KH; Wunderer A; Wechsel HW; Nelde HJ; St Krause F
Anticancer Res; 1999; 19(2C):1483-6. PubMed ID: 10365128
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the argyrophilic nucleolar organizer region, nuclear DNA content and mean nuclear area in transitional cell carcinoma of bladder using a quantitative image analyzer.
Shiina H; Urakami S; Shirakawa H; Shigeno K; Himeno Y; Mizutani M; Igawa M; Ishibe T
Eur Urol; 1996; 29(1):99-105. PubMed ID: 8821699
[TBL] [Abstract][Full Text] [Related]
11. Histopathologic prognostic indicators for renal cell carcinoma.
Delahunt B
Semin Diagn Pathol; 1998 Feb; 15(1):68-76. PubMed ID: 9503507
[TBL] [Abstract][Full Text] [Related]
12. p53 expression in correlation to clinical outcome in patients with renal cell carcinoma.
Ljungberg B; Bozoky B; Kovacs G; Stattin P; Farrelly E; Nylander K; Landberg G
Scand J Urol Nephrol; 2001 Feb; 35(1):15-20. PubMed ID: 11291681
[TBL] [Abstract][Full Text] [Related]
13. Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma.
Kamel D; Turpeenniemi-Hujanen T; Vähäkangas K; Pääkkö P; Soini Y
Histopathology; 1994 Oct; 25(4):339-47. PubMed ID: 7835839
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Urakami S; Honda S; Shirakawa H; Ishibe T
J Clin Pathol; 1996 May; 49(5):395-9. PubMed ID: 8707954
[TBL] [Abstract][Full Text] [Related]
15. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
16. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
18. [Qualitative and quantitative parameters for prognosis in renal carcinoma in early and advanced stages].
Del Vecchio MT; Spina D; Lazzi S; Bruni A; Funtò I; Mattei FM; Fornaini M; Luzi P; Tosi P
Pathologica; 1997 Aug; 89(4):390-6. PubMed ID: 9471607
[TBL] [Abstract][Full Text] [Related]
19. Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours?
Plastiras D; Moutzouris G; Barbatis C; Presvelos V; Petrakos M; Theodorou C
Eur J Surg Oncol; 1999 Feb; 25(1):61-5. PubMed ID: 10188857
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma.
Kramer BA; Gao X; Davis M; Hall M; Holzbeierlein J; Tawfik O
J Am Coll Surg; 2005 Oct; 201(4):565-70. PubMed ID: 16183495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
